Osa Surgery denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for osa surgery are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies OSA Surgery as Not FDA-Approved

A "not-FDA-approved" denial for OSA surgery most commonly arises when the specific surgical device used — most frequently a hypoglossal nerve stimulation system — is the subject of Humana's review. Humana may contend that the device lacks FDA clearance or approval, that the indication for which it was used falls outside the FDA-cleared labeling, or that post-market approval conditions have not been documented. These denials are particularly important to challenge because the FDA approval or clearance status of a device is a factual, publicly verifiable matter.

## Why This Denial Is Appealable

If the device used in your procedure has received FDA premarket approval (PMA) or 510(k) clearance, the factual premise of the denial is incorrect and must be corrected on appeal. Your surgeon and the device manufacturer can provide documentation of FDA approval status. Additionally, if the procedure was performed within the cleared indication, the denial lacks a clinical or regulatory basis. Insurers are not permitted to misstate a device's regulatory status as grounds for denial.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): File a written appeal with documentation of the device's FDA approval or clearance. Clearly identify the specific device, its FDA approval number or 510(k) number, and the date of approval.
• External review: If the internal appeal is denied, request independent external review. An IRO will assess whether Humana's characterization of the device's regulatory status is accurate. The external-review window is typically around four months from denial.
• Expedited review: Available when delay poses urgent clinical risk.

## Timeline

Act promptly. The FDA approval documentation can typically be obtained quickly from the device manufacturer or directly from the FDA's public database. Do not allow the appeal deadline to pass while gathering records.

## Documentation to Gather

• FDA approval documentation: The device's FDA premarket approval letter, 510(k) clearance letter, or equivalent regulatory document. This is publicly available on the FDA website and can also be provided by the device manufacturer's medical affairs team.
• Indication confirmation: Documentation from your surgeon confirming that the device was used in accordance with its FDA-cleared indication as described in the device labeling.
• Diagnosis and clinical records: Sleep study results, physician notes, and prior treatment history establishing the clinical basis for the procedure.
• Surgeon's letter: A letter from your operating surgeon specifically addressing the FDA approval status question and confirming on-label use.
• Applicable guideline reference: Mention by your physician of the relevant guideline organization (e.g., the American Academy of Sleep Medicine) that supports the procedure as an accepted treatment.

## Criteria-Mapping Structure

Create a document with three columns: (1) Humana's stated basis for the "not-FDA-approved" denial, (2) the FDA regulatory document number and date that refutes it, and (3) the clinical record showing on-label use. Attach the FDA document as a labeled exhibit. This format makes the factual error immediately apparent to any reviewer.